LuciTala (Talazoparib) 1mg

Another Name
Talazoparib 1mg Capsules
Indications
Talazoparib PARP Inhibitor for Breast & Prostate Cancer
Reg No
Inspection No
dosage form:Capsules
Specs:1mg x 30Capsules
Indate:2 Years
Date:2026-10-13 Views:161

COMPOSITION

Each capsule contains:
Talazoparib …………………………………… 1mg

INDICATION

LuciTala is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of:

  • Adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative, locally advanced or metastatic breast cancer, as determined by an approved diagnostic test.
  • Adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), in combination with enzalutamide.

DOSAGE AND USE

For adult patients with gBRCAm, HER2-negative, locally advanced or metastatic breast cancer, the recommended dosage of LuciTala is 1 mg orally once daily, until disease progression or unacceptable toxicity.

For adult patients with HRR gene-mutated mCRPC, the recommended dosage is 0.5 mg orally once daily in combination with enzalutamide, until disease progression or unacceptable toxicity.

Take LuciTala with or without food. Swallow capsules whole. Do not open or dissolve the capsules.

DOSAGE FORMS AND STRENGTHS

Capsules: 0.25 mg, 0.5 mg, 1 mg

STORAGE

Store at 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to 30°C (59°F to 86°F).

Keep medicine out of the reach of Children.

MANUFACTURED BY

LUCIUS PHARMACEUTICALS (LAO) CO., LTD

No. 26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING AND PRECAUTION

To be sold by retail on prescription of a Registered physician only, and as directed by the physician. Keep medicine out of reach of Children. Do not administer LuciTala during Pregnancy and Lactation.

Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/lucitala-talazoparib-1mg/

Related News